tag:blogger.com,1999:blog-26929727926516195522024-03-16T11:52:42.080-07:00Aging BiomarkersArtificially-intelligent biomarkers of human agingUnknownnoreply@blogger.comBlogger29125tag:blogger.com,1999:blog-2692972792651619552.post-53623420340457560032017-05-18T02:16:00.001-07:002017-05-18T02:16:41.356-07:00WuXi Spotlight - Insilico Medicine<iframe allowfullscreen="" frameborder="0" height="270" src="https://www.youtube.com/embed/a2XQfMJNHYs?list=PLeYDrH9AdTK0NhaZL6Qw0KxCzTBAm4YBX" width="480"></iframe>Rochhttp://www.blogger.com/profile/10226480566630388819noreply@blogger.com200tag:blogger.com,1999:blog-2692972792651619552.post-77023861902928867232017-01-15T08:14:00.001-08:002017-01-15T08:14:34.916-08:00Top 10 compound to fight ageingA recent paper published by Insilico Inc. shows that may we can fight aging using following top 10 geroprotectors. For more details check following paper<br />
<br />
<h1 class="valign" id="article-title" style="box-sizing: inherit; color: #0c1d31; font-family: Helvetica, Arial, sans-serif; font-size: 24px; letter-spacing: 0.15000000596046448px; line-height: 1.1; margin: 0px !important;">
<a href="http://www.aging-us.com/article/MHpmpbTNuNqLnCN9g/text" target="_blank">In search for geroprotectors: in silico screening and in vitro validation of signalome-level mimetics of young healthy state</a></h1>
<br />
<div>
<div class="section-container" style="box-sizing: inherit; color: #2e4057; font-family: Helvetica, Arial, sans-serif; font-size: 15px; letter-spacing: 0.15000000596046448px;">
<div class="table-title" style="background-color: #e0e0e0; background-position: initial initial; background-repeat: initial initial; border-left-color: rgb(17, 17, 17); border-left-style: solid; border-left-width: 1px; border-right-color: rgb(17, 17, 17); border-right-style: solid; border-right-width: 1px; border-top-color: rgb(17, 17, 17); border-top-style: solid; border-top-width: 1px; box-sizing: inherit; padding: 10px; text-align: center;">
<h4 style="box-sizing: inherit; font-size: 16px; font-weight: 400; line-height: 17.600000381469727px; margin: 1.14rem 0px 0.912rem;">
Table 1. Letter codes for the test conditions.</h4>
</div>
<div class="article-table" style="border: 1px solid rgb(17, 17, 17); box-sizing: inherit; margin: 0px 0px 20px; overflow: auto; padding: 0px !important;">
<table class="bordered" id="t1" style="border-collapse: collapse; border-spacing: 0px; border: none; box-sizing: inherit; width: 538.328125px;"><tbody>
<tr style="box-sizing: inherit;"><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">Cells</td><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">Substance</td><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">Code</td></tr>
<tr style="box-sizing: inherit;"><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">young</td><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">-</td><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">Y</td></tr>
<tr style="box-sizing: inherit;"><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">old</td><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">-</td><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">O</td></tr>
<tr style="box-sizing: inherit;"><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">old</td><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">Nordihydroguaiaretic acid (NDGA)</td><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">A</td></tr>
<tr style="box-sizing: inherit;"><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">old</td><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">Myricetin</td><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">B</td></tr>
<tr style="box-sizing: inherit;"><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">old</td><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">HA-1004</td><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;"><i style="box-sizing: inherit; line-height: inherit;">C</i></td></tr>
<tr style="box-sizing: inherit;"><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">old</td><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">7-Cyclopentyl-5-(4-phenoxy)phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine</td><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;"><i style="box-sizing: inherit; line-height: inherit;">D</i></td></tr>
<tr style="box-sizing: inherit;"><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">old</td><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">Staurosporine</td><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;"><i style="box-sizing: inherit; line-height: inherit;">E</i></td></tr>
<tr style="box-sizing: inherit;"><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">old</td><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">Ursolic acid</td><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;"><i style="box-sizing: inherit; line-height: inherit;">F</i></td></tr>
<tr style="box-sizing: inherit;"><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">old</td><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">N-acetyl-L-cysteine (NAC)</td><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">G</td></tr>
<tr style="box-sizing: inherit;"><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">old</td><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">Fasudil (HA-1077)</td><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">H</td></tr>
<tr style="box-sizing: inherit;"><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">old</td><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">PD-98059</td><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">I</td></tr>
<tr style="box-sizing: inherit;"><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">old</td><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">Epigallocatechin gallate (EGCG)</td><td style="border-bottom-left-radius: 2px; border-bottom-right-radius: 2px; border-top-left-radius: 2px; border-top-right-radius: 2px; border: none; box-sizing: inherit; padding: 5px; vertical-align: middle;">J</td></tr>
</tbody></table>
</div>
</div>
<div class="section-container" style="box-sizing: inherit; color: #2e4057; font-family: Helvetica, Arial, sans-serif; font-size: 15px; letter-spacing: 0.15000000596046448px;">
</div>
</div>
Rochhttp://www.blogger.com/profile/10226480566630388819noreply@blogger.com5tag:blogger.com,1999:blog-2692972792651619552.post-37057674190425057602016-05-23T07:38:00.001-07:002016-05-23T08:26:39.557-07:00Deep Neural Network For Prediction of Ageing<div>
<span style="text-align: justify;">Exiting news for people working the field of ageing, biogerontology and computational chemistry. </span></div>
<div>
<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td><span style="font-size: large; margin-left: auto; margin-right: auto;"><a href="http://www.eurekalert.org/pub_releases/2016-05/imi-ann051816.php" target="_blank"><img border="0" height="59" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgrPjxWbDUmmrslqiosdWnERqZDxhB6n3VlVtyrTjk0eDo1URxt9kvkg-9MMdDaVF4qM1UvSiheYRSFGyOd3DjPq24bDNmW2gewpev3cIvNkHIqDTabT1KgdIrZlCwl7e31Wp85FNktfZXT/s320/Screen+Shot+2016-05-22+at+4.36.28+PM.png" width="320" /></a></span></td></tr>
<tr><td class="tr-caption" style="font-size: 13px;"><h1 class="page_title" style="box-sizing: border-box; color: #2b2b2b; font-weight: 300; letter-spacing: -0.34px; line-height: 1.1; margin: 25px 0px 0px; text-align: start;">
<span style="text-align: center;"><span style="font-family: inherit; font-size: small;"><a href="http://www.eurekalert.org/pub_releases/2016-05/imi-ann051816.php" target="_blank">Artificial Neural Networks Guess Patients Age With Excellent Accuracy</a></span></span></h1>
<div>
<span style="text-align: center;"><a href="http://www.eurekalert.org/pub_releases/2016-05/imi-ann051816.php" target="_blank"><br /></a></span></div>
</td></tr>
</tbody></table>
</div>
<div>
<br /></div>
Ageing can be viewed in two ways<br />
<div>
<br /></div>
<div>
<b>a) </b>Ageing at physiological or organ system level</div>
<div>
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEim6qsD661JpG3AQvpvFMZMLjY4Sb3Z_suPfzC35hNf8xm_9ePTVnMpb4pJpfHOianQcRx_lA8E-k2IpIslP8D3NrD86WR4-NMP8kpsPv7LbuYYYbIlgavmY1hKpVUCHACMsSuLJ0YC1O7j/s1600/Screen+Shot+2016-05-22+at+4.27.25+PM.png" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" height="176" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEim6qsD661JpG3AQvpvFMZMLjY4Sb3Z_suPfzC35hNf8xm_9ePTVnMpb4pJpfHOianQcRx_lA8E-k2IpIslP8D3NrD86WR4-NMP8kpsPv7LbuYYYbIlgavmY1hKpVUCHACMsSuLJ0YC1O7j/s200/Screen+Shot+2016-05-22+at+4.27.25+PM.png" width="200" /></a><b>b)</b> Ageing at cellular level</div>
<div>
<br /></div>
<div style="text-align: justify;">
mostly ageing at cellular level is responsible for causing problems at organ system level. However, fighting ageing at cellular level by targeting single molecular pathway may not be sufficient enough due to complex dynamics in action that causes ageing to progress forward. Complexity of life can be unfolded by simplest molecules that causes an amplified effect in a bigger picture.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
We know that cancer, Alzheimer's, cardiovascular problems and others are age related diseases that lead to problems. Pathways driven by proteins like m-TOR, sirtuins and others are been explored to fight ageing. Recently Insilico. Inc undertook a systematic studied on fundamental bio-molecules and their correlation with ageing. <span style="font-size: large;">The paper can be downloaded from <a href="http://www.impactaging.com/papers/v8/n5/full/100968.html" target="_blank">here</a></span>.</div>
<div style="text-align: justify;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<iframe allowfullscreen="" class="YOUTUBE-iframe-video" data-thumbnail-src="https://i.ytimg.com/vi/l62jlwgL3v8/0.jpg" frameborder="0" height="266" src="https://www.youtube.com/embed/l62jlwgL3v8?feature=player_embedded" width="320"></iframe></div>
<div style="text-align: justify;">
<br />
The paper explains the development of a model based on 64,000 blood sample tests from human subjects. The model is based on 21 important blood test biomarkers that can be used for prediction ageing process in individuals. They have successfully identified five important biomarkers that play critical role in ageing.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
i) Albumin</div>
<div style="text-align: justify;">
ii) Glucose</div>
<div style="text-align: justify;">
iii)Alkaline phosphatase</div>
<div style="text-align: justify;">
iv) Urea and</div>
<div style="text-align: justify;">
v) Erythrocytes </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
For common people they have availed a web portal called <a href="http://www.aging.ai/">www.aging.ai</a> where by providing the blood test results, the AI can predict the age of subject with surprising high accuracy. It clearly shows the advances in the computational biology towards developing deeper and complex correlations between disease and biomolecules. In Silico Inc. is currently making considerable effort in developing deep learning solutions in the field of regenerative medicine, embryonic development, cross species comparison and new drug discovery program.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Pharma.Ai is part of Insilico.Inc that is mainly responsible for use of deep neural networks in biomedical application. The group is currently working on two major projects of analyzing </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
a) Correlation between transcriptomic data and ageing</div>
<div style="text-align: justify;">
b) Deep learned multi-disease marker and classifier </div>
<div style="text-align: justify;">
c) Predictor of mechanism of action of multiple drugs based on multi-omics data </div>
<div style="text-align: justify;">
d) Blood chemistry based marker for human ageing (One of the milestone was published recently as discussed above).<br />
<br />
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj5dcyKLPLCG6knRYub53y0r7faZfUWaStckxQPHhFL3up490MObgSUHH05D3ejXE-3UHmx2iPD2c4HMNeB7xN_Jy3PZH19cib8URWeE5X8uv79rC5S-Q2Y4LLI5AR96OmnMg2ak-fYQ6m4/s1600/Screen+Shot+2016-05-24+at+12.20.33+AM.png" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" height="132" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj5dcyKLPLCG6knRYub53y0r7faZfUWaStckxQPHhFL3up490MObgSUHH05D3ejXE-3UHmx2iPD2c4HMNeB7xN_Jy3PZH19cib8URWeE5X8uv79rC5S-Q2Y4LLI5AR96OmnMg2ak-fYQ6m4/s400/Screen+Shot+2016-05-24+at+12.20.33+AM.png" width="400" /></a>Recently Insilico Inc. is also planning to collaborate with other major institutions to find biomarkers for human ageing. <a href="http://www.eurekalert.org/pub_releases/2016-05/imi-ima051716.php" target="_blank">Please check following recent press release</a><br />
<br />
<i style="background-color: white; color: #333333; font-family: 'Open Sans', 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 14px; text-align: start;">Insilico Medicine will provide advanced signaling pathway activation analysis services to evaluate differential changes between healthy tissues and those affected by disease as well as comparing tissues of different ages. In addition to signaling pathway analysis, parties intend to develop artificially-intelligent comprehensive biomarkers of human aging based on large sample data sets.</i></div>
<div style="text-align: justify;">
<br /></div>
Rochhttp://www.blogger.com/profile/10226480566630388819noreply@blogger.com14tag:blogger.com,1999:blog-2692972792651619552.post-20225214886123144082016-02-28T05:19:00.003-08:002016-02-28T05:37:41.331-08:00I-Robots for Age DiagnosisThere has been substantial boom in the field of artificial intelligence. It is important for people to understand that one can fight ageing with following perspectives:<br />
<br />
a) Anti-ageing molecules/ Cosmetics<br />
<i><br /></i>
<i>and also with</i><br />
<br />
b) Artificial Intelligence (AI).<br />
<br />
<div style="text-align: justify;">
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhKdrEqUd41LBliXtRGq8FBe2fEGGm1C-xPNKP5PdhyphenhyphenYEKOq-lByQm9YTWk8LA0KCH0aHnMfbYE2fwqk7GQcrM0DkHQVpasNMfJ8DZJOQzBpplSmLirDnifp2fhoMqdmqPQNz7BRVnWQgHw/s1600/Screen+Shot+2016-02-28+at+7.22.36+PM.png" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" height="82" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhKdrEqUd41LBliXtRGq8FBe2fEGGm1C-xPNKP5PdhyphenhyphenYEKOq-lByQm9YTWk8LA0KCH0aHnMfbYE2fwqk7GQcrM0DkHQVpasNMfJ8DZJOQzBpplSmLirDnifp2fhoMqdmqPQNz7BRVnWQgHw/s400/Screen+Shot+2016-02-28+at+7.22.36+PM.png" width="400" /></a></div>
Fighting ageing with AI/ i-robot is thought to increase by tenfolds in next five years. This may help in fighting cancer and come up with newer and better algorithms on cancer diagnosis or mapping the efficacy of chemo on your smart phones. <a href="http://www.agingbiomarkers.com/2016/02/mobile-app-to-map-ageing.html">Mapping ageing with face scanning or taking selfies</a> was the first step of Insilico Inc. As a next step, they have launched new website; where by using simple blood test an AI on the backend can predict the age of subjects. </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
<a href="http://aging.ai/">Please check here:</a> It is a web portal that is scientifically tested and available for free usage. Moreover, it is developed with an aim of identifying markers that are responsible for ageing. People often discuss about food habits, drinking adequate amount of water, doing exercise and other activities for becoming healthy and fit. But does it really work? It certainly keeps human body fit and active but does it help in slowing the ageing process?</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In order to answer such questions it is important to develop a correlation data between basic factors effecting ageing and dietary habits. However, to establish this relation only handful of information is available on the markers of ageing (for e.g. <a href="xhttp://www.agingcell.com/2015/10/important-breakthroughs-in-cancer-and.html">Telomeres,</a><a href="http://www.agingcell.com/2015/10/important-breakthroughs-in-cancer-and.html"> m-TOR</a>, <a href="http://www.agingcell.com/2016/02/anti-ageing-drugs-and-molecules.html">Sirtuins</a> etc). Important thing to notice is that the "Blood" remains in contact with all the human tissues. This is an important material or matrix which carries common materials that are most essential to human cells and tissues with varied morphologies and activities. Hence, may be the answer to finding markers perhaps be hidden somewhere in this red fluid as shown by Insilico Inc. by <a href="http://aging.ai/">launching algorithm</a> that maps ageing based on blood test data.</div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
In addition Aging.ai developed by Insilico Inc and RYNKL's <a href="http://www.agingbiomarkers.com/2016/02/mobile-app-to-map-ageing.html"> wrinkle reading app (as discussed previously)</a>; Microsoft has also developed a new age mapping web portal for free that answers a most basic question "How Old Do I look?"</div>
<div style="text-align: justify;">
<br /></div>
<div class="separator" style="clear: both; text-align: left;">
<iframe allowfullscreen="" class="YOUTUBE-iframe-video" data-thumbnail-src="https://i.ytimg.com/vi/8W0yKdDzk_Y/0.jpg" frameborder="0" height="266" src="https://www.youtube.com/embed/8W0yKdDzk_Y?feature=player_embedded" width="320"></iframe></div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Even though we ponder on the question "Is ageing a disease?". Well, there is no "Official" answer to this question yet. But the data shows that people are so obsessed with ageing that it took just 7 days to reach around 50 million users for microsoft's fancy tool (as discussed in video). May be we don't need any official notification to testify that "Ageing is a disease". </div>
<div style="text-align: justify;">
<br /></div>
<div style="text-align: justify;">
Leaders like Microsoft, Insilco Inc, SENSE foundation and other organisations are constantly finding newer ways to fight ageing by learning about how ageing happens. Facial feature recognition AI by Microsoft and RYNKL may provide a fun time for people post their predicted age and post it on Facebook, Twitter or any other social media site. But apart from fun time this is concept of predicting ageing perhaps also be applied to predicting the occurrence of age related disease like cancer.</div>
Rochhttp://www.blogger.com/profile/10226480566630388819noreply@blogger.com4tag:blogger.com,1999:blog-2692972792651619552.post-88647556031015064962016-02-18T06:13:00.001-08:002016-02-18T06:13:28.258-08:00Insilico Medicine launches Aging.AI -- deep-learned predictor of age trained on blood tests<a href="http://www.eurekalert.org/pub_releases/2016-02/imi-iml021716.php#.VsXRdPN48rB.blogger">Insilico Medicine launches Aging.AI -- deep-learned predictor of age trained on blood tests</a>: Insilico Medicine launched aging.AI, a system allowing users to guess their age and gender by entering the results of their blood test.Unknownnoreply@blogger.com5tag:blogger.com,1999:blog-2692972792651619552.post-55979318454614947192016-02-11T06:43:00.001-08:002016-02-19T22:09:09.453-08:00Mobile App to Map AgeingAs you all must be knowing that researchers from Insilco Inc are constantly working to find newer ways to fight ageing. Researchers often study ageing at cellular and molecular level. The most obvious and prompt signature of ageing is "Face". People often use many skin care products such as powder, cream, lotions, face masks, anti-wrinkle creams etc. to prevent ageing.<br />
<br />
It is astonishing that according to <a href="http://www.statista.com/statistics/254612/global-skin-care-market-size/">statista database</a> global anti ageing market is increasing exponentially with time and it will be increasing to 154 million USD by 2021.<br />
<br />
<div style="font-family: Helvetica; font-size: 12px; line-height: normal;">
<br /></div>
<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh70zWiMOgUlwQSGcbwavCs10K0DTEwpO0LyUwR9yRQHxP-hWPOzL7BKSBm0_AaAkKidTwRp5QsLdCczCedOjgyMKgVnqdJ2pMTpXkOP6Otl51NJBY6E1miHDKDPSAKpVjlfaUpjoSbI1nX/s1600/5.jpg" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" height="204" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh70zWiMOgUlwQSGcbwavCs10K0DTEwpO0LyUwR9yRQHxP-hWPOzL7BKSBm0_AaAkKidTwRp5QsLdCczCedOjgyMKgVnqdJ2pMTpXkOP6Otl51NJBY6E1miHDKDPSAKpVjlfaUpjoSbI1nX/s320/5.jpg" width="320" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><b>Figure 1: </b>Skin Care Product Market</td></tr>
</tbody></table>
<br />
However, few important questions:<br />
<br />
a) Does these products really work?<br />
b) How should you quantitatively track the efficacy of the product you are applying?<br />
c) Is it worth looking at your face for hours in mirror to find if the products work or not?<br />
<br />
Interestingly, researchers have developed a new mobile app with an artificial intelligence that can quantitatively map ageing of your face. A team lead by Dr. Alex Zhavaronkov shows that it is possible to map ageing using this app. And see how the anti-ageing products are working over time.<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<iframe allowfullscreen="" class="YOUTUBE-iframe-video" data-thumbnail-src="https://i.ytimg.com/vi/5mBTpNCfaNQ/0.jpg" frameborder="0" height="266" src="https://www.youtube.com/embed/5mBTpNCfaNQ?feature=player_embedded" width="320"></iframe></div>
<br />
The app is available for android users for free and can be <a href="http://rynkl.com/"><b>downloaded </b></a>on your android smart phones. For IOS users the app is going to be launched soon in February. Please register <b><a href="http://rynkl.com/#rec3648670">here</a> </b>for your notification of the app once it is launched. It was pretty amazing app so I tried it by myself and check my score to find out how does it works in figures shown below.<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjwl_OyR3Pc2ZkgCaisZDx7gv1qrTogmgdd0rr6JfQ9t47lnMjSt0reaNNLUOe9uOx-4n6fOyoGLtcXMU2TkArTEd3Wx4mWERJTgo8RfA0D_A26U1stmy8BdPR_jTJCO7ERRaBbeMdISZW4/s1600/1.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="190" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjwl_OyR3Pc2ZkgCaisZDx7gv1qrTogmgdd0rr6JfQ9t47lnMjSt0reaNNLUOe9uOx-4n6fOyoGLtcXMU2TkArTEd3Wx4mWERJTgo8RfA0D_A26U1stmy8BdPR_jTJCO7ERRaBbeMdISZW4/s320/1.jpg" width="320" /></a></div>
<br />
Although the pic shows a pretty glamorous girl by app..I am a guy. We need to upload the selfies as per the instructions given by Dr. Zhavaronkov and map ageing based on wrinkles. My score shows as 5.0 that indicates that my skin is healthy and I am beautiful (fewer wrinkle lesser number). This app can even help people to see if their anti ageing product is working or not.<br />
<br />
<blockquote class="tr_bq" style="text-align: center;">
<b><i><a href="https://play.google.com/store/apps/details?id=com.rynkl">Try this app it is fun and very useful</a></i></b></blockquote>
<br />
Please check this video for more details.<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<iframe allowfullscreen="" class="YOUTUBE-iframe-video" data-thumbnail-src="https://i.ytimg.com/vi/2DxRDzGAIU0/0.jpg" frameborder="0" height="266" src="https://www.youtube.com/embed/2DxRDzGAIU0?feature=player_embedded" width="320"></iframe></div>
<br />
Moreover, <a href="http://beauty.ai/">Beauty.AI</a> have updated their first list of winner based on age. The contest was judged by robot jury created by<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhIuwOtSOFEHN9HLKWiPg_Yj_-XCnlt9QFdGrDl_-eNK4z2M24ijZAsEikjiTeJwATV5SeU5cjNlqdgapE5tODlsleZxEavjnd77mqOHxNoGGyYYN2LgP2diH4W1p9qC8U3RF3Za_WLW_Jr/s1600/Screen+Shot+2016-02-11+at+11.08.28+PM.png" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" height="60" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhIuwOtSOFEHN9HLKWiPg_Yj_-XCnlt9QFdGrDl_-eNK4z2M24ijZAsEikjiTeJwATV5SeU5cjNlqdgapE5tODlsleZxEavjnd77mqOHxNoGGyYYN2LgP2diH4W1p9qC8U3RF3Za_WLW_Jr/s200/Screen+Shot+2016-02-11+at+11.08.28+PM.png" width="200" /></a></div>
<br />
a) RYNKL: Wrinkle Detector<br />
b) MADIS: Model Alliance Digital Intelligence Scout<br />
c) Symmetry: Master<br />
<br />
<h2>
<b>Algorithm to Map Ageing</b></h2>
In addition to this app the Insilico Inc also launched a newly advanced algorithm to map ageing in humans by checking blood glucose and cholesterol levels. You can just feed in the data about your latest blood tests and AI will guess your age and sex. The AI is already trained for million samples.<br />
<span style="background-color: white; color: #222222; font-size: 15px;"><i><span style="font-family: inherit;"><b>The algorithm can guess sex, without using hormone levels, with 99% accuracy, and guess your age within a ten-year window at least 60% accuracy using ten key measurements found in a standard blood test</b></span></i></span><br />
<br />
<span style="font-family: inherit;"><span style="background-color: white; color: #222222; font-size: 15px;">Dr. </span><span style="background-color: white; color: #222222; font-size: 15px;">Zhavoronkov says</span></span><i style="color: #222222; font-family: inherit; font-size: 15px;">“We want robots to look at human lifespan as a game,” he said — a game that artificial intelligence can help us win.</i><br />
<br />
<span style="color: #222222; font-family: inherit;"><span style="background-color: white; font-size: 15px;">You can get more details about this news <a href="http://www.dailynewsx.com/news/science-news/this-medical-company-created-an-online-calculator-that-uses-ai-to-guess-your-age-and-sex-34922.html">article here........</a> or at <a href="http://www.techinsider.io/insilico-medicine-guess-your-age-blood-test-2016-2">tech insider</a> or at <a href="http://www.eurekalert.org/pub_releases/2016-02/imi-iml021716.php">eurekalert</a>. </span></span><br />
<br />Rochhttp://www.blogger.com/profile/10226480566630388819noreply@blogger.com5tag:blogger.com,1999:blog-2692972792651619552.post-10684088172535085452015-11-17T02:57:00.001-08:002015-11-17T02:58:31.143-08:00Diagnosis of ageing<a href="http://www.agingcell.com/2015/10/ageing-cancer-dependency.html">Cancer is age related disease</a>. We know that ageing is an inevitable process. <a href="http://www.agingcell.com/2015/11/is-ageing-really-disease.html">Perhaps, someday it will be officially included as disease in upcoming ICD-11 going to get updated in 2018</a>.<br />
<br />
And perhaps someday we will have better answers one the most sought after question: Is it possible to have long life? Or in other words Can we attain longevity? Although, there are important clues from nature about the long life For e.g. Hydra, <a href="http://www.agingcell.com/2015/11/cancer-resistant-and-long-living-rodent.html">Nake Mole Rat</a> and others. We have examples like a <b style="color: #252525; font-family: sans-serif; font-size: 14px;">Jeanne Louise Calment</b>. She was the longest living human on earth. May be sometime in near future we will have answer to question of living longer life.<br />
<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEikfc-F-zNhfH0GcLnjCvF6kl7RVwh2_6OnLKZ3AA0_owH9tRllUCrl35A3kxA8F3HnXZ0AsEwX2esCUNUdb51mHFmwsvhg3370JzrDlNwHBlUEPKzfjZzmEvXnmJwT0W_l6ZXWkOzaWl_C/s1600/jeanne-calment.jpg" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" height="140" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEikfc-F-zNhfH0GcLnjCvF6kl7RVwh2_6OnLKZ3AA0_owH9tRllUCrl35A3kxA8F3HnXZ0AsEwX2esCUNUdb51mHFmwsvhg3370JzrDlNwHBlUEPKzfjZzmEvXnmJwT0W_l6ZXWkOzaWl_C/s200/jeanne-calment.jpg" width="200" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Jeanne Louise Calment </td></tr>
</tbody></table>
122 year old lady<br />
<br />
But to face this problem of ageing we must know how to diagnose it. We need reliable methods by which we can carry out diagnosis of ageing.<br />
<br />
<blockquote class="tr_bq">
<i><span style="font-family: Georgia, Times New Roman, serif;"><span style="font-family: "georgia", "times new roman", serif;">Crazy</span><span style="font-family: georgia, times new roman, serif;"> thought...It is ironic that if ageing is never been classified as disease then why do we need to diagnosis it? </span></span></i></blockquote>
<br />
Moving towards an important idea of diagnosis of human ageing. A recent paper published by group of scientists in Genome Biology Journal developed a unique transcriptomic method for diagnosis of human ageing. The published article is open access please click <a href="http://www.genomebiology.com/2015/16/1/185"><i>here</i></a>.<br />
<br />
Paper claims to find a new method using statistically robust multi-tissue RNA signature from peripheral blood samples of human subject's healthy ageing that can be use for diagnosis of future health.<br />
<!--[if gte mso 9]><xml>
<o:DocumentProperties>
<o:Revision>0</o:Revision>
<o:TotalTime>0</o:TotalTime>
<o:Pages>1</o:Pages>
<o:Words>128</o:Words>
<o:Characters>734</o:Characters>
<o:Company>BioNano </o:Company>
<o:Lines>6</o:Lines>
<o:Paragraphs>1</o:Paragraphs>
<o:CharactersWithSpaces>861</o:CharactersWithSpaces>
<o:Version>14.0</o:Version>
</o:DocumentProperties>
<o:OfficeDocumentSettings>
<o:AllowPNG/>
</o:OfficeDocumentSettings>
</xml><![endif]-->
<!--[if gte mso 9]><xml>
<w:WordDocument>
<w:View>Normal</w:View>
<w:Zoom>0</w:Zoom>
<w:TrackMoves/>
<w:TrackFormatting/>
<w:PunctuationKerning/>
<w:ValidateAgainstSchemas/>
<w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
<w:IgnoreMixedContent>false</w:IgnoreMixedContent>
<w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
<w:DoNotPromoteQF/>
<w:LidThemeOther>EN-US</w:LidThemeOther>
<w:LidThemeAsian>JA</w:LidThemeAsian>
<w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
<w:Compatibility>
<w:BreakWrappedTables/>
<w:SnapToGridInCell/>
<w:WrapTextWithPunct/>
<w:UseAsianBreakRules/>
<w:DontGrowAutofit/>
<w:SplitPgBreakAndParaMark/>
<w:EnableOpenTypeKerning/>
<w:DontFlipMirrorIndents/>
<w:OverrideTableStyleHps/>
<w:UseFELayout/>
</w:Compatibility>
<m:mathPr>
<m:mathFont m:val="Cambria Math"/>
<m:brkBin m:val="before"/>
<m:brkBinSub m:val="--"/>
<m:smallFrac m:val="off"/>
<m:dispDef/>
<m:lMargin m:val="0"/>
<m:rMargin m:val="0"/>
<m:defJc m:val="centerGroup"/>
<m:wrapIndent m:val="1440"/>
<m:intLim m:val="subSup"/>
<m:naryLim m:val="undOvr"/>
</m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
<w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"
DefSemiHidden="true" DefQFormat="false" DefPriority="99"
LatentStyleCount="276">
<w:LsdException Locked="false" Priority="0" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Normal"/>
<w:LsdException Locked="false" Priority="9" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>
<w:LsdException Locked="false" Priority="39" Name="toc 1"/>
<w:LsdException Locked="false" Priority="39" Name="toc 2"/>
<w:LsdException Locked="false" Priority="39" Name="toc 3"/>
<w:LsdException Locked="false" Priority="39" Name="toc 4"/>
<w:LsdException Locked="false" Priority="39" Name="toc 5"/>
<w:LsdException Locked="false" Priority="39" Name="toc 6"/>
<w:LsdException Locked="false" Priority="39" Name="toc 7"/>
<w:LsdException Locked="false" Priority="39" Name="toc 8"/>
<w:LsdException Locked="false" Priority="39" Name="toc 9"/>
<w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>
<w:LsdException Locked="false" Priority="10" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Title"/>
<w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>
<w:LsdException Locked="false" Priority="11" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>
<w:LsdException Locked="false" Priority="22" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Strong"/>
<w:LsdException Locked="false" Priority="20" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>
<w:LsdException Locked="false" Priority="59" SemiHidden="false"
UnhideWhenUsed="false" Name="Table Grid"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>
<w:LsdException Locked="false" Priority="1" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 1"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 1"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 1"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>
<w:LsdException Locked="false" Priority="34" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>
<w:LsdException Locked="false" Priority="29" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Quote"/>
<w:LsdException Locked="false" Priority="30" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 1"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 1"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 2"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 2"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 2"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 2"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 2"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 3"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 3"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 3"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 3"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 3"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 4"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 4"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 4"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 4"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 4"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 5"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 5"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 5"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 5"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 5"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 6"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 6"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 6"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 6"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 6"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>
<w:LsdException Locked="false" Priority="19" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>
<w:LsdException Locked="false" Priority="21" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>
<w:LsdException Locked="false" Priority="31" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>
<w:LsdException Locked="false" Priority="32" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>
<w:LsdException Locked="false" Priority="33" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>
<w:LsdException Locked="false" Priority="37" Name="Bibliography"/>
<w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/>
</w:LatentStyles>
</xml><![endif]-->
<!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:"";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin:0cm;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:"Times New Roman";}
</style>
<![endif]-->
<!--StartFragment-->
<!--EndFragment--><br />
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjp38BQgnKnlAtFHvS3wsbl0zrHQXEKaOr1wEIIEa84cKn6aVgltw99QtirenDWDxx0SwWwCKqdoNBfcR5oCHyjpdjM57G5p4f9MKVMly0dZOYwko6ysnfZd2FvWej3YSuipzbMNcKDriLf/s1600/s13059-015-0750-x-1.gif" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" height="320" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjp38BQgnKnlAtFHvS3wsbl0zrHQXEKaOr1wEIIEa84cKn6aVgltw99QtirenDWDxx0SwWwCKqdoNBfcR5oCHyjpdjM57G5p4f9MKVMly0dZOYwko6ysnfZd2FvWej3YSuipzbMNcKDriLf/s320/s13059-015-0750-x-1.gif" width="276" /></a></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
"Figure: 1 Development,
validation and clinical application of ageing diagnostic. Overview of the
selection process and use of RNA probe-sets for the development and validation
of the healthy physiological age classifier. We identified useful probe-sets
from a possible starting number of ~54,000 during step one [e.g. probe-sets
with leave-one-out cross-validation (LOOCV) performance ≥ 90 %]. We then
evaluated the performance of the top-ranked 150 probe-sets in a number of
independent muscle, brain, and skin samples, demonstrating that the signature
was diagnostic for age. We then applied the 150-probe-set healthy ageing
signature to several clinical studies, as illustrated at the end of the
workflow. Key features included discarding the training data set immediately
after selecting the 150 probe-sets and relying on LOOCV and full external
validation processes"<o:p></o:p></div>
<br />
<br />
There is no commercial method available for diagnosis of human ageing. But may be this paper will provide an important step in the field of diagnosis of human ageing.<br />
<br />Rochhttp://www.blogger.com/profile/10226480566630388819noreply@blogger.com10tag:blogger.com,1999:blog-2692972792651619552.post-25749548636479810092015-05-04T20:52:00.001-07:002015-05-05T06:25:18.886-07:00Insilico Medicine SuperPharman Challenge: Looking for Superheroes to Fight Aging and Transform the Pharmaceutical Industry<h2 style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 13.333333969116211px; text-align: center;">
<span style="font-family: Arial;">Insilico Medicine is Searching for Super Heroes to Fight Aging</span></h2>
<div style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 13.333333969116211px;">
<span style="font-family: Arial;"><br /></span></div>
<div style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 13.333333969116211px;">
<span style="font-family: Arial;"><br />Aging fighters at Insilico Medicine are looking for relentless doers who dream big, but are not afraid to get their hands dirty with basic tasks. Doers, who have trouble sleeping at night, because they know that millions of people are suffering and dying of cancer and age-related diseases and their own clock is ticking as well. Doers with both programming and database management skills and knowledge of biology. You will need to know or quickly learn how to use huge multi-omics data to find alternative uses of currently available drugs and distribute many micro tasks to the crowd, freelancers or colleagues, while keeping the big picture in mind. </span><br />
<span style="font-family: Arial;"></span><br />
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgDwJoqAG0whQl4EkhsAH_PN7KWvuMfGEisx0mT3OBXfYmfvBgDWEWQvyG8c7JaFS8uEPkh5tRk9_1S9j2PZzDuXJ3U2aLD0_0pKvvwukJAh1-oGmZUHCRkNAI0RftzN0Nt44MRQZWu9WU/s1600/TransPharman1+-+Leader.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" height="320" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgDwJoqAG0whQl4EkhsAH_PN7KWvuMfGEisx0mT3OBXfYmfvBgDWEWQvyG8c7JaFS8uEPkh5tRk9_1S9j2PZzDuXJ3U2aLD0_0pKvvwukJAh1-oGmZUHCRkNAI0RftzN0Nt44MRQZWu9WU/s320/TransPharman1+-+Leader.jpg" width="320" /></a><span style="font-family: Arial;">We know that we are looking for a needle in the haystack, but this is how our team has come to be and you will be in great company. We have relentless super heroes in the US, UK, Switzerland, Poland, Israel, Russia and China. If you know someone amazing, who fits that profile amazing, ask him. Maybe he or she is already working for us. He goes through the day doing a boring academic job, but at night he is hacking away.</span><br />
<br />
<span style="font-family: Arial;">Our first frontier is transforming the pharmaceutical industry, repurposing known drugs and finding the new ones. When we launch, the world will become a better place. And if you are that super hero with bold ideas and hands on experience, ready to unleash maniacal energy to hack aging, send us a signal and we will respond right away or start watching you to see if you fit.</span></div>
<div style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 13.333333969116211px;">
<span style="font-family: Arial; font-size: x-small;"><br /></span></div>
<div style="background-color: white;">
<span style="color: #222222; font-family: arial, sans-serif; font-size: 13.333333969116211px;">Here is a link to what Insilico Medicine is doing: </span></div>
<div style="background-color: white;">
<span style="color: #222222; font-family: arial, sans-serif; font-size: 13.333333969116211px;"><br /></span></div>
<div class="separator" style="clear: both; text-align: center;">
<iframe allowfullscreen="" class="YOUTUBE-iframe-video" data-thumbnail-src="https://i.ytimg.com/vi/hWUqZmDBJLc/0.jpg" frameborder="0" height="266" src="https://www.youtube.com/embed/hWUqZmDBJLc?feature=player_embedded" width="320"></iframe></div>
<div style="background-color: white;">
<span style="background-color: transparent;"><br /></span></div>
<div style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 13.333333969116211px;">
<span style="font-family: Arial; font-size: x-small;">In partnerships they can also do in vitro and in vivo validation, humouse clinical trials and even organ-on-a-chip and body-on-a-chip validation. </span><span style="font-family: Arial;"></span><br />
<span style="font-family: Arial;">They are looking for someone with similar skill set and energy as Alex Zhavoronkov (<a href="http://www.linkedin.com/in/zhavoronkov" style="color: #1155cc;" target="_blank"><span style="color: #042eee;"><u>www.linkedin.com/in/<wbr></wbr>zhavoronkov</u></span></a>) to work together with him, gradually replace him and then find someone to replace yourself as the company grows or you decide to start a subsidiary. </span><br />
<span style="font-family: Arial;"></span><br />
<span style="font-family: Arial;"><b>Minimum requirements:</b></span><br />
<ul>
<li><span style="font-family: Arial; font-size: 13.333333969116211px;">Python, MySQL, Hadoop, AWS Services, IBM Watson</span></li>
<li><span style="font-family: Arial; font-size: 13.333333969116211px;">Experience working with multi-omics data and/or clinical trials/biomedical text data</span></li>
<li><span style="font-family: Arial; font-size: 13.333333969116211px;">SVM and deep learning algorithms</span></li>
<li><span style="font-family: Arial; font-size: 13.333333969116211px;">Basic knowledge of signaling and metabolic pathways</span></li>
<li><span style="font-family: Arial; font-size: 13.333333969116211px;">Experience working with GEO, ArrayExpress, KEGG, TCGA, LINCS, Connectivity Map, Drugbank, Clinical Trials, WHO databases, etc.</span></li>
<li><span style="font-family: Arial; font-size: 13.333333969116211px;">Personal network of contacts in academia and large pharmaceutical companies</span></li>
<li><span style="font-family: Arial; font-size: 13.333333969116211px;">Excellent writing skills</span></li>
<li><span style="font-family: Arial; font-size: x-small;">Ability to give public talks and generate publicity is a plus</span></li>
<li><span style="font-family: Arial; font-size: 13.333333969116211px;">Knowledge of Russian, Chinese or Hebrew is a plus</span></li>
</ul>
</div>
<br />
<div>
<br /></div>
<div>
<br /></div>
<div>
<br /></div>
Unknownnoreply@blogger.com225tag:blogger.com,1999:blog-2692972792651619552.post-35073690568869589962015-01-04T02:51:00.000-08:002015-01-04T02:51:12.153-08:00Major policy conference on the future of aging and longevity<div style="text-align: center;">
Please consider attending this notable conference in London in February</div>
<div style="text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjvOM0NEjM-jqzM2vu3oi3b6UTz1Qwoly9HUFT4ATUSyi2xofQU0kqH40WvAWKh4j6X1eAR7DWs1ErVwqin2J-I60Z-VqHw3_AV53NlnbbNGm0lxViQsSRHr89ltJBacT4I7Z8Mb_s9EWI/s1600/Chatham+Event+Banner.jpg" height="47" width="400" /><a href="http://www.chathamhouse.org/conferences/ageing">http://www.chathamhouse.org/conferences/ageing</a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
In addition to academic and government luminaries in the field you will be able to meet representatives of the Biogerontology Research Foundation</div>
Unknownnoreply@blogger.com5tag:blogger.com,1999:blog-2692972792651619552.post-88876356200259719522014-10-03T04:17:00.001-07:002014-10-03T04:17:08.945-07:00Everyday drugs could give extra years of life - New ScientistGreat article on New Scientist by the talented science journalist Clare Wilson covering the Aging Forum.<br /><br />
<br /><br />
<a href="http://www.newscientist.com/article/mg22429894.000-everyday-drugs-could-give-extra-years-of-life.html#.VC6FS5Gf1-f.blogger">Everyday drugs could give extra years of life - health - 01 October 2014 - New Scientist</a>Unknownnoreply@blogger.com3tag:blogger.com,1999:blog-2692972792651619552.post-24344247055038084432014-06-26T20:14:00.002-07:002014-06-26T20:14:46.110-07:00Should we Treat Aging as a Disease? Academic, pharmaceutical, healthcare policy and pension fund perspectives<div style="line-height: 15.0pt; margin-bottom: 12.0pt; margin-left: 0in; margin-right: 0in; margin-top: 12.0pt;">
<span style="color: #333333; font-family: Helvetica; font-size: 11.0pt;">Are you an expert in biomedical sciences, medical doctor,
economist, data scientist, actuary, pensions fund manager? Would you like to
influence research, healthcare and retirement policy and help governments,
companies and individuals prepare for the rapidly changing future?<br />
Please consider contributing a research paper, review, perspective or opinion
to the new research topic in Frontiers in Genetics, "Should we Treat Aging
as a Disease? Academic, pharmaceutical, healthcare policy and pension fund
perspectives". <o:p></o:p></span></div>
<div style="-webkit-text-stroke-width: 0px; line-height: 15.0pt; margin-bottom: 12.0pt; margin-left: 0in; margin-right: 0in; margin-top: 12.0pt; orphans: auto; text-align: start; widows: auto; word-spacing: 0px;">
<span style="color: #333333; font-family: Helvetica; font-size: 11.0pt;">Here is the link:<br /><a href="http://www.frontiersin.org/genetics_of_aging/researchtopics/should_we_treat_aging_as_a_dis/3133">http://www.frontiersin.org/genetics_of_aging/researchtopics/should_we_treat_aging_as_a_dis/3133</a><o:p></o:p></span></div>
<!--[if gte mso 9]><xml>
<o:OfficeDocumentSettings>
<o:AllowPNG/>
</o:OfficeDocumentSettings>
</xml><![endif]-->
<!--[if gte mso 9]><xml>
<w:WordDocument>
<w:View>Normal</w:View>
<w:Zoom>0</w:Zoom>
<w:TrackMoves/>
<w:TrackFormatting/>
<w:PunctuationKerning/>
<w:ValidateAgainstSchemas/>
<w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
<w:IgnoreMixedContent>false</w:IgnoreMixedContent>
<w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
<w:DoNotPromoteQF/>
<w:LidThemeOther>EN-US</w:LidThemeOther>
<w:LidThemeAsian>JA</w:LidThemeAsian>
<w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
<w:Compatibility>
<w:BreakWrappedTables/>
<w:SnapToGridInCell/>
<w:WrapTextWithPunct/>
<w:UseAsianBreakRules/>
<w:DontGrowAutofit/>
<w:SplitPgBreakAndParaMark/>
<w:EnableOpenTypeKerning/>
<w:DontFlipMirrorIndents/>
<w:OverrideTableStyleHps/>
<w:UseFELayout/>
</w:Compatibility>
<m:mathPr>
<m:mathFont m:val="Cambria Math"/>
<m:brkBin m:val="before"/>
<m:brkBinSub m:val="--"/>
<m:smallFrac m:val="off"/>
<m:dispDef/>
<m:lMargin m:val="0"/>
<m:rMargin m:val="0"/>
<m:defJc m:val="centerGroup"/>
<m:wrapIndent m:val="1440"/>
<m:intLim m:val="subSup"/>
<m:naryLim m:val="undOvr"/>
</m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
<w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"
DefSemiHidden="true" DefQFormat="false" DefPriority="99"
LatentStyleCount="276">
<w:LsdException Locked="false" Priority="0" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Normal"/>
<w:LsdException Locked="false" Priority="9" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>
<w:LsdException Locked="false" Priority="39" Name="toc 1"/>
<w:LsdException Locked="false" Priority="39" Name="toc 2"/>
<w:LsdException Locked="false" Priority="39" Name="toc 3"/>
<w:LsdException Locked="false" Priority="39" Name="toc 4"/>
<w:LsdException Locked="false" Priority="39" Name="toc 5"/>
<w:LsdException Locked="false" Priority="39" Name="toc 6"/>
<w:LsdException Locked="false" Priority="39" Name="toc 7"/>
<w:LsdException Locked="false" Priority="39" Name="toc 8"/>
<w:LsdException Locked="false" Priority="39" Name="toc 9"/>
<w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>
<w:LsdException Locked="false" Priority="10" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Title"/>
<w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>
<w:LsdException Locked="false" Priority="11" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>
<w:LsdException Locked="false" Priority="22" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Strong"/>
<w:LsdException Locked="false" Priority="20" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>
<w:LsdException Locked="false" Priority="0" SemiHidden="false"
UnhideWhenUsed="false" Name="Table Grid"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>
<w:LsdException Locked="false" Priority="1" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 1"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 1"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 1"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>
<w:LsdException Locked="false" Priority="34" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>
<w:LsdException Locked="false" Priority="29" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Quote"/>
<w:LsdException Locked="false" Priority="30" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 1"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 1"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 2"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 2"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 2"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 2"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 2"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 3"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 3"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 3"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 3"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 3"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 4"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 4"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 4"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 4"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 4"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 5"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 5"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 5"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 5"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 5"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 6"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 6"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 6"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 6"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 6"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>
<w:LsdException Locked="false" Priority="19" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>
<w:LsdException Locked="false" Priority="21" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>
<w:LsdException Locked="false" Priority="31" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>
<w:LsdException Locked="false" Priority="32" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>
<w:LsdException Locked="false" Priority="33" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>
<w:LsdException Locked="false" Priority="37" Name="Bibliography"/>
<w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/>
</w:LatentStyles>
</xml><![endif]-->
<!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:"";
mso-padding-alt:0in 5.4pt 0in 5.4pt;
mso-para-margin:0in;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;}
</style>
<![endif]-->
<!--StartFragment-->
<!--EndFragment--><br />
<div style="-webkit-text-stroke-width: 0px; line-height: 15.0pt; margin-bottom: 12.0pt; margin-left: 0in; margin-right: 0in; margin-top: 12.0pt; orphans: auto; text-align: start; widows: auto; word-spacing: 0px;">
<span style="color: #333333; font-family: Helvetica; font-size: 11.0pt;">Frontiers is one of the top credible open access publishers
co-owned by the Nature Publishing Group. It is staying ahead of the other OA
publishers by introducing the cutting edge tools for scientists to disseminate
their research and ideas.<br />
<br />
The burden of the aging on the economies of the developed countries in the form
of rapidly increasing dependency ratios and unfunded social security and healthcare
liabilities is turning the quest to increase healthy life spans into a pressing
economic priority required to preserve the current standards of living. There
is an urgent need to develop and validate interventions with geroprotective
properties to increase the productive health spans of the working population
and maintaining performance and avoiding loss of function.<br />
<br />
The key opinion leaders in academia, the pension fund community, government and
pharmaceutical industry have voiced concerns about the possible crisis and made
calls to transform the current research and healthcare paradigms to focus on
increasing the healthy productive longevity by refocusing the efforts from
treatment to prevention.<br />
<br />
One of the impediments for the industry transformation is the way aging is
treated. And while no doubt exists that aging is a complex multifactorial
process with no single cause or treatment, the issue whether aging can be
classified as the disease is widely debated. This disagreement leads to the inability
to classify aging as a disease and fit the possible treatment options into the
established research, regulatory, insurance and marketing frameworks. Is it
time to put the philosophical disagreements aside and start treating aging as
the disease in a concerted attempt to increase productive longevity?<br />
<br />
The intent of this research topic is to combine the perspectives and reviews
from the representatives of the academic and non-profit research community as
well as from the pension funds, insurance organizations and pharmaceutical
companies.<o:p></o:p></span></div>
<div style="-webkit-text-stroke-width: 0px; line-height: 15.0pt; margin-bottom: 12.0pt; margin-left: 0in; margin-right: 0in; margin-top: 12.0pt; orphans: auto; text-align: start; widows: auto; word-spacing: 0px;">
Please consider attending one of the most important conferences on bridging aging research between academia and industry - <a href="http://www.agingpharma.org/">www.AgingPharma.org</a>. Details also available at <a href="http://www.biotechnologymeetings.com/">www.BiotechnologyMeetings.com</a> </div>
Unknownnoreply@blogger.com3tag:blogger.com,1999:blog-2692972792651619552.post-38435769698980033252014-03-12T17:53:00.001-07:002014-03-12T17:53:46.188-07:00A scheme guide to changing longevity risk - Comment & Analysis - Pensions Expert<a href="http://www.pensions-expert.com/Comment-Analysis/A-scheme-guide-to-changing-longevity-risk#.UyEBi57pQNY.blogger">A scheme guide to changing longevity risk - Comment & Analysis - Pensions Expert</a>Unknownnoreply@blogger.com1tag:blogger.com,1999:blog-2692972792651619552.post-26479538068374131502014-03-05T16:29:00.001-08:002014-03-05T16:29:58.086-08:00Signaling pathway cloud regulation for in silico screening and ranking of the potential geroprote...<div dir="ltr" style="line-height: 1.15; margin-bottom: 0pt; margin-top: 0pt;"><span style="background-color: white; color: black; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: bold; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">Scientists propose the new in silico method for high throughput screening and ranking of the possible geroprotector drugs to fight aging</span></div><div dir="ltr" style="line-height: 1.15; margin-bottom: 0pt; margin-top: 12pt;"><span style="background-color: white; color: black; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">Aging is one of the major challenges of the modern society. The advances in biomedicine and healthcare systems have led to the unprecedented long lives of the population after the retirement leading to the increased burden on the economies. There is an urgent need to develop and validate interventions with geroprotective properties to increase the productive health spans of the working population and maintaining performance and avoiding loss of function.</span></div><div dir="ltr" style="line-height: 1.15; margin-bottom: 0pt; margin-top: 12pt;"><span style="background-color: white; color: black; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">Experiments with animal models already resulted in significant breakthroughs resulting in up to 1,000 percent increases in lifespans. But extrapolating these advances to humans or other mammals proved to be extremely challenging. Human live orders of magnitude longer than the short-lived model organisms and there is no comprehensive set of aging biomarkers, allowing to track the effects of the many drugs that may extend lifespan. We are also different from other animals and the many drugs that work on mice do not work on humans. </span></div><div dir="ltr" style="line-height: 1.15; margin-bottom: 0pt; margin-top: 12pt;"><span style="background-color: white; color: black; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">To address these challenges the international team comprised of biogerontologists, geneticists, computer scientists and biomathematicians proposed using a computer simulation and laboratory validation approach using human cells and model organisms to predict what drugs may help fight aging in humans. </span></div><div dir="ltr" style="line-height: 1.15; margin-bottom: 0pt; margin-top: 12pt;"><span style="background-color: white; color: black; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">The Human Genome Project and the following revolution in sequencing and laboratory diagnostics resulted in the vast data on genetic and epigenetic profiles of cells and tissues from people of various ages. The proposed method uses this data to construct the cloud of molecular signalling pathways involved in aging and longevity and evaluates the effects of the very large number of drugs and drug combinations to simulate the young state of the cells and tissues. Scientists hope that this method may be used to find new drugs with aging-suppressive properties and predict the activity of the drugs that are already on the market. Also, people respond to the drugs differently and this method may be able to personalize the geroprotective therapy to the individual patients and help the drug companies conduct better clinical trials. </span></div><div dir="ltr" style="line-height: 1.15; margin-bottom: 0pt; margin-top: 12pt;"><span style="background-color: white; color: black; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">"There are thousands of compounds with known molecular targets and some are already used in the clinic. Due to high cost and the time it takes to complete the experimental work, it may not be possible to test all of the effects of these drugs even in mice. And the fact that the drug works in mice does not guarantee the same effect in humans. There needs to be a better way to predict the efficacy of the drug in humans. We proposed a method for doing that in silico using the multiple sources of data and we hope to validate this method in the very near future.", said Alex Zhavoronkov, PhD, the director of the Biogerontology Research Foundation in the UK. "Also, people are different, age at different rates and respond to drugs differently. The proposed method may be used to predict the personalized geroprotector regiments.", he added. </span></div><div dir="ltr" style="line-height: 1.15; margin-bottom: 0pt; margin-top: 12pt;"><span style="background-color: white; color: black; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">Many pharmaceutical companies already expressed their interest in bringing aging research into clinical practice, but the absence of the business models, accurate validation methods, and the inability to classify aging as the curable disease are major impediments to mainstream development of geroprotective drugs. In silico drug discovery may help accelerate this process. The group plans to present the results of their experimental work using this method at the Practical Applications of Aging Research Symposium at MipTek 2014 in Basel, Switzerland attended by over 3,000 delegates from the pharmaceutical industry. </span></div><div dir="ltr" style="line-height: 1.15; margin-bottom: 0pt; margin-top: 12pt;"><span style="background-color: white; color: black; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">“The decreases in cost and increased availability of genetic and epigenetic research as well as the breakthroughs in computer technologies are already helping make better decisions in biomedicine. The proposed method may take the in silico approach to drug discovery to the next level. If the can validate it in the laboratory, and we are working on that as we speak, this may revolutionize aging research”, said Anton Buzdin, the director of the First Oncology Research and Advisory Center.</span></div><b id="docs-internal-guid-c2113a78-94cc-e773-52fc-2d5b8906b6db" style="font-weight: normal;"><br /><span style="background-color: transparent; color: black; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"></span></b><br />
<div dir="ltr" style="line-height: 1.15; margin-bottom: 0pt; margin-top: 0pt;"><a href="http://journal.frontiersin.org/Journal/10.3389/fgene.2014.00049/abstract" style="text-decoration: none;"><span style="background-color: transparent; color: #1155cc; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: underline; vertical-align: baseline; white-space: pre-wrap;">The paper</span></a><span style="background-color: transparent; color: black; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"> describing the new approach to screening and ranking of geroprotective drugs was published in the reputable scientific journal </span><a href="http://journal.frontiersin.org/" style="text-decoration: none;"><span style="background-color: transparent; color: #1155cc; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: underline; vertical-align: baseline; white-space: pre-wrap;">Frontiers in Genetics</span></a><span style="background-color: transparent; color: black; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">. </span></div><br /><br />
<div dir="ltr" style="line-height: 1.15; margin-bottom: 0pt; margin-top: 0pt;"><span style="background-color: transparent; color: black; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">Citation: Zhavoronkov A, Buzdin AA, Garazha AV, Borissoff N and Moskalev AA (2014). Signaling pathway cloud regulation for in silico screening and ranking of the potential geroprotective drugs. Front. Genet. 5:49. doi: 10.3389/fgene.2014.00049 - See more at: </span><span style="background-color: transparent; color: #1155cc; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: underline; vertical-align: baseline; white-space: pre-wrap;"><a href="http://journal.frontiersin.org/Journal/10.3389/fgene.2014.00049/abstract#sthash.2qpLbytY.dpuf" style="text-decoration: none;">http://journal.frontiersin.org/Journal/10.3389/fgene.2014.00049/abstract#sthash.2qpLbytY.dpuf</a></span><span style="background-color: transparent; color: black; font-family: 'Times New Roman'; font-size: 16px; font-style: normal; font-variant: normal; font-weight: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"></span></div><div dir="ltr" style="line-height: 1.15; margin-bottom: 0pt; margin-top: 0pt;"><br /></div><a href="http://www.frontiersin.org/Journal/10.3389/fgene.2014.00049/full#sthash.5Ln1dVoI.cmfs">Signaling pathway cloud regulation for in silico screening and ranking of the potential geroprote...</a>Unknownnoreply@blogger.com3tag:blogger.com,1999:blog-2692972792651619552.post-48463756572167829562013-10-21T16:28:00.001-07:002013-10-21T16:28:20.546-07:00Young scientist's quest to defeat aging<br />
It is always a pleasure to see the young scientists working on their projects with passion and dedication. It is even a greater pleasure to see some of the outstanding ones trying to popularize research in their field. Maria Litovchenko, a young scientist, who recently graduated from the Moscow Institute of Physics and Technology and is doing her graduate work at LMU Muenschen is running an excellent blog – <a href="http://www.labfairy.com/" target="_blank">Laboratory Fairy (www.LabFairy.com) </a>. It is a pleasure to see someone truly dedicated to defeating aging through excellence in scientific research.<br />
<br />
We would like to wish her all the best in her endeavors.<br />
Unknownnoreply@blogger.com2tag:blogger.com,1999:blog-2692972792651619552.post-38091272155120690952013-10-01T02:19:00.000-07:002013-10-01T02:19:20.945-07:00A team of Russian scientists drills into the problem of age-related mineralization of the connective tissue
<!--[if gte mso 9]><xml>
<o:OfficeDocumentSettings>
<o:AllowPNG/>
</o:OfficeDocumentSettings>
</xml><![endif]-->
<!--[if gte mso 9]><xml>
<w:WordDocument>
<w:View>Normal</w:View>
<w:Zoom>0</w:Zoom>
<w:TrackMoves/>
<w:TrackFormatting/>
<w:PunctuationKerning/>
<w:ValidateAgainstSchemas/>
<w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
<w:IgnoreMixedContent>false</w:IgnoreMixedContent>
<w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
<w:DoNotPromoteQF/>
<w:LidThemeOther>EN-US</w:LidThemeOther>
<w:LidThemeAsian>JA</w:LidThemeAsian>
<w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
<w:Compatibility>
<w:BreakWrappedTables/>
<w:SnapToGridInCell/>
<w:WrapTextWithPunct/>
<w:UseAsianBreakRules/>
<w:DontGrowAutofit/>
<w:SplitPgBreakAndParaMark/>
<w:EnableOpenTypeKerning/>
<w:DontFlipMirrorIndents/>
<w:OverrideTableStyleHps/>
</w:Compatibility>
<m:mathPr>
<m:mathFont m:val="Cambria Math"/>
<m:brkBin m:val="before"/>
<m:brkBinSub m:val="--"/>
<m:smallFrac m:val="off"/>
<m:dispDef/>
<m:lMargin m:val="0"/>
<m:rMargin m:val="0"/>
<m:defJc m:val="centerGroup"/>
<m:wrapIndent m:val="1440"/>
<m:intLim m:val="subSup"/>
<m:naryLim m:val="undOvr"/>
</m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
<w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"
DefSemiHidden="true" DefQFormat="false" DefPriority="99"
LatentStyleCount="276">
<w:LsdException Locked="false" Priority="0" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Normal"/>
<w:LsdException Locked="false" Priority="9" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>
<w:LsdException Locked="false" Priority="39" Name="toc 1"/>
<w:LsdException Locked="false" Priority="39" Name="toc 2"/>
<w:LsdException Locked="false" Priority="39" Name="toc 3"/>
<w:LsdException Locked="false" Priority="39" Name="toc 4"/>
<w:LsdException Locked="false" Priority="39" Name="toc 5"/>
<w:LsdException Locked="false" Priority="39" Name="toc 6"/>
<w:LsdException Locked="false" Priority="39" Name="toc 7"/>
<w:LsdException Locked="false" Priority="39" Name="toc 8"/>
<w:LsdException Locked="false" Priority="39" Name="toc 9"/>
<w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>
<w:LsdException Locked="false" Priority="10" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Title"/>
<w:LsdException Locked="false" Priority="0" Name="Default Paragraph Font"/>
<w:LsdException Locked="false" Priority="11" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>
<w:LsdException Locked="false" Priority="22" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Strong"/>
<w:LsdException Locked="false" Priority="20" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>
<w:LsdException Locked="false" Priority="59" SemiHidden="false"
UnhideWhenUsed="false" Name="Table Grid"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>
<w:LsdException Locked="false" Priority="1" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 1"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 1"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 1"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>
<w:LsdException Locked="false" Priority="34" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>
<w:LsdException Locked="false" Priority="29" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Quote"/>
<w:LsdException Locked="false" Priority="30" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 1"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 1"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 2"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 2"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 2"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 2"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 2"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 3"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 3"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 3"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 3"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 3"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 4"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 4"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 4"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 4"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 4"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 5"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 5"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 5"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 5"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 5"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 6"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 6"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 6"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 6"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 6"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>
<w:LsdException Locked="false" Priority="19" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>
<w:LsdException Locked="false" Priority="21" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>
<w:LsdException Locked="false" Priority="31" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>
<w:LsdException Locked="false" Priority="32" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>
<w:LsdException Locked="false" Priority="33" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>
<w:LsdException Locked="false" Priority="37" Name="Bibliography"/>
<w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/>
</w:LatentStyles>
</xml><![endif]-->
<!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:"";
mso-padding-alt:0in 5.4pt 0in 5.4pt;
mso-para-margin:0in;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:10.0pt;
font-family:Cambria;}
</style>
<![endif]-->
<!--StartFragment-->
<br />
<div class="MsoNormal">
When you open a 70-year old patient on the operating table
and touch the aorta, the feeling may resemble touching an eggshell or sand
paper. It is stiffer than the heart of a young person and the key reasons for
this are the abundant calcium deposits in the connective tissue that accumulate
with age. <o:p></o:p></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
The many factors leading to mineralization of the connective
tissue include genetic and acquired diseases, inflammation, reactive oxygen
species, but the major problem is that it occurs spontaneously during aging as
calcium-containing molecules are trapped in the extracellular matrix and
develop into apatite over time. <o:p></o:p></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
Despite its relative significance, compared to the many
other areas of aging research, mineralization of the connective tissue is
rarely mentioned in scientific publications and few teams are working on
preventing or clearing out the extracellular aggregates. To address the problem, a multidisciplinary
team of physicians, bioinformatitians, biochemists and physicists performed a
comprehensive bioinformatics analysis of the many factors involved in
mineralization, identified key molecular targets and proposed a list of
possible drugs to address the issue. <o:p></o:p></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
The results of the study were accepted for publication by a
high-impact journal in biogerontology “Rejuvenation Research” and will be
published shortly and can be cited as “Mineralization of the connective tissue:
a complex molecular process leading to age-related loss of function”, Anastasia
Shindyapina, Garik V Mkrtchyan, Tatiana Gneteeva, Sveatoslav Buiucli, M Kulka,
B Tancowny, Alexander Aliper, Alexander Zhavoronkov, Rejuvenation Research,
ahead of print. doi:10.1089/rej.2013.1475, <a href="http://online.liebertpub.com/doi/abs/10.1089/rej.2013.1475"><span style="color: windowtext; text-decoration: none; text-underline: none;">http://online.liebertpub.com/doi/abs/10.1089/rej.2013.1475</span></a> ,
PMID 23902273<o:p></o:p></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
Anastasia Shindyapina together with her collaborators
presented the results of the study on the 5<sup>th</sup> of September at the
SENS6 conference in Cambridge, UK.<o:p></o:p></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
“Aging inevitably leads to the loss of function on many
levels. Mineralization of the connective tissue is one of the causes and
consequences of aging and is a complex multifactorial process. Metabolic
activity, diseases and external stress factors may cause calcification, but
most importantly, it occurs spontaneously. Our goal is to identify least toxic
ways to both prevent calcification and to repair the accumulated aggregates.”, said Anastasia Shindyapina,
ASUS Fellow for Bioinformatics and Medical Information Technology,
PhD-candidate at the Moscow State University and researcher at FOIRMYS. <o:p></o:p></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
"Mineralization of connective tissue with age is one of
the many aspects of aging that are examples of "accumulation of eventually
pathogenic extracellular material", an issue that attracts too little
attention within the academic community. The accumulation of advanced glycation
endproducts (AGEs) and of mineral deposits both result in increased stiffness
of connective tissue, impair homeostasis and contribute to a broad range of
age-related diseases. Through comprehensive bioinformatic analysis of the many
molecular processes involved in mineralization, Zhavoronkov's team has
identified possible molecular interventions. Additionally they proposed that
mineralization and AGEs work in concert and should be addressed concurrently.
Anastasia Shyndyapina, the lead author on the paper, recently presented this
work at the SENS6 conference in Cambridge.", commented Dr. Aubrey de Grey,
Chief Science Officer of SENS Research Foundation and International Adjunct
Professor at the Moscow Institute of Physics and Technology (MIPT).<o:p></o:p></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<b>About FOIRMYS<o:p></o:p></b></div>
<div class="MsoNormal">
The First Open Institute for Regenerative Medicine for Young
Scientists (FOIRMYS) is a non-profit volunteer initiative bringing together
over a thousand enthusiast young scientists and physicians interested in
regenerative medicine. It was first organized by <a href="http://www.amazon.com/author/aging"><span style="color: windowtext; text-decoration: none; text-underline: none;">Alex Zhavoronkov</span></a>, PhD in
collaboration with Sergey Yakovenko, PhD, Sergey Roumiantsev, PhD and Oleg
Korzinov in Moscow with support from <a href="http://en.wikipedia.org/wiki/Anna_Chapman">Anna Chapman</a>. <o:p></o:p></div>
<div class="MsoNormal">
FOIRMYS provides regular weekly lectures by the top academic
and industry thought leaders, investors and regulators. The list of presenters
includes Paolo Macchiarini (Karolinska Institute), Alexey Aravin (Caltech), Charles
Cantor (Boston U, ex-director of the Human Genome Project), Augustinus Bader
(Leipzig University), top managers from Beijing Genomics Institute, Malaysian
Genome Resource Center, Indigo Capital Partners and many others. As part of the
curriculum students participate in practicums at “<a href="http://www.altravita.ru/">Altravita IVF</a>, <a href="http://www.fnkc.ru/">FRCCPH</a>,
<a href="http://www.oncofinder.com/">FORCC</a>, <a href="http://www.q-pharm.com/">Quantum
Pharmaceuticals</a>, <a href="http://www.pharmcluster.ru/">Biopharmcluster
“Northern”</a> and <a href="http://www.mipt.ru/">Moscow Institute of Physics and
Technology</a>. <o:p></o:p></div>
<div class="MsoNormal">
Members work in small teams comprised of scientists and
physicians on ambitious outlier projects in aging and regenerative medicine
with topics ranging from mineralization of connective tissue, HGPS and
regulation of endometriosis to industry overviews and healthcare economics. The
projects are coordinated in a crowdsourced environment and rely heavily on popular
tools like Facebook, Dropbox and Google Apps. FOIRMYS developed a concept
called “Personalized Medicine”, where projects are centered around the problems
of a single patient, who provides samples and helps coordinate the project. Members
also learn how to promote their work, create personal science blogs (including
Women in Science initiative) and engage in industry outreach. <o:p></o:p></div>
<div class="MsoNormal">
Participation in practical group projects resulted in
success stories including young scientists’ publications in peer-reviewed
journals, fellowships, participation in international conferences, gainful
employment of young scientists and international collaborations. <o:p></o:p></div>
<div class="MsoNormal">
<br /></div>
<!--EndFragment-->Unknownnoreply@blogger.com1tag:blogger.com,1999:blog-2692972792651619552.post-70932440751997807022013-08-10T09:18:00.000-07:002013-08-10T09:20:07.071-07:00The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy featured on CBS RadioAlex Zhavoronkov, the author of "The Ageless Generation" is interviewed by Dan Raviv of CBS Radio.<br />
<br />
The interview is <a href="http://www.agingbiomarkers.com/2013/08/the-ageless-generation-how-advances-in.html">available here</a>:<br />
http://audio.cbsradionewsfeed.com/2013/08/09/15/W0040809_1801_2523613.mp3<br />
<br />Unknownnoreply@blogger.com1tag:blogger.com,1999:blog-2692972792651619552.post-42039421726740948612013-05-27T19:01:00.002-07:002013-05-27T19:01:30.740-07:00The Aging Generation Book Website is Now LiveOne of the hottest books advocating for accelerating the aging research and refocusing research activities to extend healthy productive life span, "<a href="http://www.amazon.com/The-Ageless-Generation-Biomedicine-Transform/dp/0230342205/">The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy</a>" now has a <a href="http://www.agelessbook.com/">Website</a>.<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://www.agelessbook.com/newsletter-signup/"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEihCFdTPC9yp8o4mZ6oHIkjOu3uo1rT2gIGR_TSeH5gEehFZRWuUBz3IYZtNOaT0oTNof9G4zMpRXiYbQ-jUo10fBWMDYRz2nDJzTEVuu1qFsaA1RzxHifJgcKDTeaXZO_bnnHFZjPiDto/s1600/btn-newsletter.png" /><span id="goog_547578905"></span></a><span id="goog_547578906"></span></div>
<br />Unknownnoreply@blogger.com1tag:blogger.com,1999:blog-2692972792651619552.post-12953219441057383252013-04-02T18:47:00.002-07:002013-04-02T18:47:55.255-07:00The best biomarker of agingIs peer review... <br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiJujDvFEVRAr6yExphoJqzC1H6hGq9Sdz6K98X0iiMvmRgNt2brispeYhCcT-nmrTc7KVGJ4REUlt9h2K1YOZpzTMm3Oyvp11WUmBU67Ve9YOybtEHSPWg7cYc3iSEzVHWsW7K_jX3x-v5/s1600/Anti-Aging-Skin-care.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="227" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiJujDvFEVRAr6yExphoJqzC1H6hGq9Sdz6K98X0iiMvmRgNt2brispeYhCcT-nmrTc7KVGJ4REUlt9h2K1YOZpzTMm3Oyvp11WUmBU67Ve9YOybtEHSPWg7cYc3iSEzVHWsW7K_jX3x-v5/s320/Anti-Aging-Skin-care.jpg" width="320" /></a></div>
<br /><br />Happy fool's day. Sorry, we missed it ;)Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-2692972792651619552.post-892861551437735102009-12-08T06:08:00.000-08:002009-12-08T06:10:39.145-08:00Disease biomarkers and aging biomarkers may be the same?<a onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}" href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhk4ML0FbOEHZU7wbBLvC4SVbMQzyEHmywBsuxawQPhnf7tMoIkOoQ-JDhYG-MKZtQgihre_hYl4CP9Oh_3HAcWzHB2HXRT_VQK4WMTWzlO3-USBxyU_1YBulHKDHT4ch8wcf4qERNWX4c/s1600-h/blog.JPG"><img style="display:block; margin:0px auto 10px; text-align:center;cursor:pointer; cursor:hand;width: 320px; height: 239px;" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhk4ML0FbOEHZU7wbBLvC4SVbMQzyEHmywBsuxawQPhnf7tMoIkOoQ-JDhYG-MKZtQgihre_hYl4CP9Oh_3HAcWzHB2HXRT_VQK4WMTWzlO3-USBxyU_1YBulHKDHT4ch8wcf4qERNWX4c/s320/blog.JPG" border="0" alt=""id="BLOGGER_PHOTO_ID_5412867046804963378" /></a><br />Chronic age-related diseases. Age-related changes in the<br />proteome have been described and were found to be highly similar<br />to changes associated with chronic diseases. We give several<br />examples on the successful application of proteomics in the diagnosis,<br />prognosis and therapy of these chronic diseases. Longstanding<br />diabetes is associated with a decline in renal function<br />and diabetic nephropathy has become the most prevalent cause of<br />end-stage renal disease. Patients with type 2 diabetes particularly<br />progress to severe life-threatening coronary artery disease,<br />the leading cause of morbidity and mortality worldwide. Cancer<br />can be considered a chronic disease predominately observed<br />in the second half of life. Taken together, urological tumors of the<br />prostate and the bladder are the most incident malignancies<br />in the United States followed by breast cancer, and cause more<br />than 35% of incidences. Essentially, all clinical proteomic investigations<br />indicate that the approach to combine several disease-associated<br />markers to a clearly distinct panel appears to be well suited<br />for disease diagnosis, staging, progression, and for assessment<br />of prognosis of these chronic diseases.<br /><br /><br />Gerontology. 2009;55(2):123-37. Epub 2009 Jan 9.<br />Proteomics in gerontology: current applications and future aspects--a mini-review.<br /><br />Schiffer E, Mischak H, Zimmerli LU.<br /><br />Mosaiques Diagnostics and Therapeutics AG, Hannover, Germany. schiffer@mosaiques-diagnostics.comUnknownnoreply@blogger.com1tag:blogger.com,1999:blog-2692972792651619552.post-24535474643812169272009-08-09T10:18:00.000-07:002009-08-09T10:19:27.614-07:00Biomarkers of Aging and Disease: Introduction and Definitions.The concept of biomarkers of aging and age-related disease began to appear in the gerontologic and geriatric literature in the early 1980s as investigators were wrestling with the disconnect between chronological age and lifespan across and within species. In those early days, the interest was in eliminating the confounding influence of disease from research on aging so that biomarkers of underlying processes of aging could be developed (Ludwig & Smoke, 1981; Reff & Schneider, 1982; Sprott & Schneider, 1985). The question of what was aging and what was disease was at the core of the development of scientific legitimacy for the young science of aging. A key question then (and in some places now) was whether aging and disease were separate entities or aging was simply the end result (sum of damage) of a lifetime of disease. Adherents of the "aging is disease" view held that biomarkers of aging, separate from disease were not possible. Adherents of the "aging is the result of basic underlying processes" argued that aging research needed to be conducted with disease free subjects (human and lower animal) in order to be valid. Biomarkers of aging would then be markers of the progress of these underlying processes.<br /><br />Exp Gerontol. 2009 Jul 31<br />Biomarkers of Aging and Disease: Introduction and Definitions.<br />Sprott RLUnknownnoreply@blogger.com6tag:blogger.com,1999:blog-2692972792651619552.post-39133322801093490632009-06-24T06:49:00.000-07:002009-06-24T06:56:55.467-07:00Cortisol awakening rise in middle-aged women in relation to psychological stress.The cortisol awakening rise (CAR) is defined as cortisol secretory activity in the first 45-60min immediately post-awakening. It has been suggested that psychological factors may disrupt the normal awakening rise. Recent research has shown that psychological stress may influence the magnitude of the CAR, however the findings have been mixed. This study examined the impact of stress on the CAR and the diurnal mean in a sample of middle-aged women.<br />The results suggest that psychological stress may be associated with a smaller cortisol awakening rise, a lower diurnal mean, poor lifestyle choices and high levels of psychological distress. These findings may have broader implications for future health risk and for an individual's ability to cope with imminent daily stressors and demands.<br /><br />Psychoneuroendocrinology. 2009 Jun 9. <br />O'Connor DB, Hendrickx H, Dadd T, Elliman TD, Willis TA, Talbot D, Mayes AE, Thethi K, Powell J, Dye L.Unknownnoreply@blogger.com2tag:blogger.com,1999:blog-2692972792651619552.post-33457626457315448882009-06-17T21:38:00.000-07:002009-06-17T21:42:20.919-07:00Cancer and SenescenceVery interesting article in the March issue of Cancer Research Journal:<br /><br />Abstract<br />Senescence is an irreversible arrest triggered by stresses such as telomere shortening, DNA damage, or oncogenic signaling. Oncogene-induced senescence occurs in preneoplastic lesions, but it is absent from full-blown malignancies suggesting a tumor suppressor function. We recently found that depletion of the receptor CXCR2 [which binds to chemokines such as interleukin (IL)-8 or GROalpha] delays both replicative senescence and impairs the senescence response to oncogenic signals. Our findings suggest that signaling by IL-8 and GROalpha might limit tumor growth by reinforcing senescence early in tumorigenesis. The challenge remains in how to integrate this with the well-known tumor promoting effects of IL-8 and GROalpha.<br /><br />A role for CXCR2 in senescence, but what about in cancer?<br />Acosta JC, Gil J.<br />Cancer Res. 2009 Mar 15;69(6):2167-70. Epub 2009 Mar 10.Unknownnoreply@blogger.com2tag:blogger.com,1999:blog-2692972792651619552.post-75164911297253541472009-06-10T01:45:00.000-07:002009-06-10T01:46:44.426-07:00Cathepsin d and eukaryotic translation elongation factor 1 as promising markers of cellular senescence.Induction of premature senescence may be a promising strategy for cancer treatment. However, biomarkers for senescent cancer cells are lacking. To identify such biomarkers, we performed comparative proteomic analysis of MCF7 human breast cancer cells undergoing cellular senescence in response to ionizing radiation (IR). IR-induced senescence was associated with up-regulation of cathepsin D (CD) and down-regulation of eukaryotic translation elongation factor 1beta2 (eEF1B2), as confirmed by Western blot. The other elongation factor, eukaryotic translation elongation factor 1alpha1 (eEF1A1), was also down-regulated. IR-induced senescence was associated with similar changes of CD and eEF1 (eEF1A1 and eEF1B2) levels in the HCT116 colon cancer cell line and the H460 lung cancer cell line. Up-regulation of CD and down-regulation of eEF1 seemed to be specific to senescence, as they were observed during cellular senescence induced by hydrogen peroxide or anticancer drugs (camptothecin, etoposide, or 50 ng doxorubicin) but not during apoptosis induced by Taxol or 10 microg doxorubicin or autophagy induced by tamoxifen. The same alterations in CD and eEF1A1 levels were observed during replicative senescence and Ras oncogene-induced senescence. Transient cell cycle arrest did not alter levels of eEF1 or CD. Chemical inhibition of CD (pepstatin A) and small interfering RNA-mediated knockdown of CD and eEF1 revealed that these factors participate in cell proliferation. Finally, the senescence-associated alteration in CD and eEF1 levels observed in cell lines was also observed in IR-exposed xenografted tumors. These findings show that CD and eEF1 are promising markers for the detection of cellular senescence induced by a variety of treatments.<br /><br />Byun HO, Han NK, Lee HJ, Kim KB, Ko YG, Yoon G, Lee YS, Hong SI, Lee JS.<br />Cancer Res. 2009 Jun 1;69(11):4638-47.Unknownnoreply@blogger.com3tag:blogger.com,1999:blog-2692972792651619552.post-9216460259787678102009-06-03T01:52:00.000-07:002009-06-03T02:15:54.968-07:00Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging.Summary Expression of the p16(INK4a) tumor suppressor sharply increases with age in most mammalian tissues, and contributes to an age-induced functional decline of certain self-renewing compartments. These observations have suggested that p16(INK4a) expression could be a biomarker of mammalian aging. To translate this notion to human use, we determined p16(INK4a) expression in cellular fractions of human whole blood, and found highest expression in peripheral blood T-lymphocytes (PBTL). We then measured INK4/ARF transcript expression in PBTL from two independent cohorts of healthy humans (170 donors total), and analyzed their relationship with donor characteristics. Expression of p16(INK4a), but not other INK4/ARF transcripts, appeared to exponentially increase with donor chronologic age. Importantly, p16(INK4a) expression did not independently correlate with gender or body-mass index, but was significantly associated with tobacco use and physical inactivity. In addition, p16(INK4a) expression was associated with plasma interleukin-6 concentration, a marker of human frailty. These data suggest that p16(INK4a) expression in PBTL is an easily measured, peripheral blood biomarker of molecular age.<br /><br /> <div class="authors"><!--AuthorList--><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Liu%20Y%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><b>Liu Y</b></a>, <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Sanoff%20HK%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><b>Sanoff HK</b></a>, <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Cho%20H%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><b>Cho H</b></a>, <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Burd%20CE%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><b>Burd CE</b></a>, <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Torrice%20C%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><b>Torrice C</b></a>, <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Ibrahim%20JG%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><b>Ibrahim JG</b></a>, <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Thomas%20NE%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><b>Thomas NE</b></a>, <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Sharpless%20NE%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus"><b>Sharpless NE</b></a>.<br /><br /><span class="ti"><span title="Aging cell."><a href="javascript:AL_get(this,%20'jour',%20'Aging%20Cell.');">Aging Cell.</a></span> 2009 May 22. </span><br /></div>Unknownnoreply@blogger.com2tag:blogger.com,1999:blog-2692972792651619552.post-28675416837303247812009-05-25T23:50:00.001-07:002009-05-25T23:50:53.565-07:00Role of visceral adipose tissue in aging.Visceral fat (VF) accretion is a hallmark of aging in humans. Epidemiologic studies have implicated abdominal obesity as a major risk factor for insulin resistance, type 2 diabetes, cardiovascular disease, stroke, metabolic syndrome and death. Utilizing novel rodent models of visceral obesity, studies have demonstrated a causal relationship between VF and age-related diseases. In contrast, surgically removing large quantities of subcutaneous (SC) abdominal fat does not consistently improve metabolic parameters in humans or rodents, suggesting that SC fat accrual is not an important contributor to metabolic decline. There is also compelling evidence in humans that abdominal obesity is a stronger risk factor for mortality risk than general obesity. Likewise, we have shown that surgical removal of VF improves mean and maximum lifespan in rats, providing the first causal evidence that VF depletion may be an important underlying cause of improved lifespan with CR. Given the hazards of VF accumulation on health, treatment strategies aimed at selectively depleting VF should be considered as a viable tool to effectively reduce disease risk in humans. In summary, this review provides both corollary and causal evidence for the importance of accounting for body fat distribution, and specifically VF, when assessing disease and mortality risk.<br /><br />Huffman DM, Barzilai N.<br />Biochim Biophys Acta. 2009 Jan 30.Unknownnoreply@blogger.com1